aav2 Search Results


96
PackGene Biotech lnc aav2 cas9
Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection <t>of</t> <t>AAV2-mCherry</t> (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
Aav2 Cas9, supplied by PackGene Biotech lnc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/AAV2+Vector+Production/pmc12930510-150-8-14
Average 96 stars, based on 1 article reviews
aav2 cas9 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

86
Obio Technology Corp Ltd aav2
Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection <t>of</t> <t>AAV2-mCherry</t> (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
Aav2, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/9+aav2+ef1/pm41922345-218-22-27
Average 86 stars, based on 1 article reviews
aav2 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

93
Addgene inc aav2 tetbow vectors
Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection <t>of</t> <t>AAV2-mCherry</t> (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
Aav2 Tetbow Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/AAV2-miniSOG-VAMP2-T2A-mCherry+(Plasmid+%2350970)/10__7554_slash_elife__40350-338-0-7
Average 93 stars, based on 1 article reviews
aav2 tetbow vectors - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Addgene inc addgene plasmid repository
Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection <t>of</t> <t>AAV2-mCherry</t> (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
Addgene Plasmid Repository, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/AAV2_hSyn_Phobos_Citrine+(Plasmid+%2398216)/pm29097684-417-8-8
Average 90 stars, based on 1 article reviews
addgene plasmid repository - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

91
OriGene anti aav vp1 vp2 vp3 rabbit polyclonal
Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection <t>of</t> <t>AAV2-mCherry</t> (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
Anti Aav Vp1 Vp2 Vp3 Rabbit Polyclonal, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/Adeno-Associated+Virus+2+%2F+AAV2+(VP1+%2B+VP2+%2B+VP3)+Rabbit+Polyclonal+Antibody/10__21203_slash_rs__3__rs___1895370_slash_v1-263-27-31
Average 91 stars, based on 1 article reviews
anti aav vp1 vp2 vp3 rabbit polyclonal - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Addgene inc plasmid phobos ca citrine
(A) Left: Engineering strategy yielding Aion and <t>Phobos</t> CADN , two new blue-shifted, step-function ACRs with temporally extended conducting states. Mutation of the D156 residue to either C or N (yielding Aion and Phobos CADN , respectively) greatly slows down the closing kinetics of the ACRs compared to its parental construct <t>Phobos</t> <t>CA</t> . The generated variants are highlighted by a black frame. Right: Schematic of Aion indicating point mutations (triangles) at the relative position within the respective transmembrane helix. (B) Representative photocurrent traces of the slow-cycling ACRs Phobos CA , Aion, Phobos CADN , and Gt ACR1 CA activated by a short 20 ms light pulse at indicated wavelengths and irradiance of 3.35 mW/mm 2 (460nm) and 3.14 mW/mm 2 (505 nm). (C) Left: quantification of peak photocurrent ( I p ) and photocurrent 30 s post illumination ( I 30s ) for each ACR. Right: photocurrent ratio at 30 s compared to the peak. (D) Normalized photocurrent after light shutoff. (E) Closing time constants (τ off ) for each ACR. For (C) and (E), black lines correspond to mean values ± SEM, and circles are single measurement data points (n PhobosCA = 5 -6 cells, nAion = 5 - 10 cells, n PhobosCADN = 8 - 9 cells, n Gt ACR1CA = 6 cells). Kruskal- Wallis test with Dunn’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001.
Plasmid Phobos Ca Citrine, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/AAV2_hSyn_Phobos_CA_Citrine+(Plasmid+%2398218)/bio_rxiv__2022__02__25__481932-219-16-22
Average 93 stars, based on 1 article reviews
plasmid phobos ca citrine - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

a1  (OriGene)
91
OriGene a1
(A) Left: Engineering strategy yielding Aion and <t>Phobos</t> CADN , two new blue-shifted, step-function ACRs with temporally extended conducting states. Mutation of the D156 residue to either C or N (yielding Aion and Phobos CADN , respectively) greatly slows down the closing kinetics of the ACRs compared to its parental construct <t>Phobos</t> <t>CA</t> . The generated variants are highlighted by a black frame. Right: Schematic of Aion indicating point mutations (triangles) at the relative position within the respective transmembrane helix. (B) Representative photocurrent traces of the slow-cycling ACRs Phobos CA , Aion, Phobos CADN , and Gt ACR1 CA activated by a short 20 ms light pulse at indicated wavelengths and irradiance of 3.35 mW/mm 2 (460nm) and 3.14 mW/mm 2 (505 nm). (C) Left: quantification of peak photocurrent ( I p ) and photocurrent 30 s post illumination ( I 30s ) for each ACR. Right: photocurrent ratio at 30 s compared to the peak. (D) Normalized photocurrent after light shutoff. (E) Closing time constants (τ off ) for each ACR. For (C) and (E), black lines correspond to mean values ± SEM, and circles are single measurement data points (n PhobosCA = 5 -6 cells, nAion = 5 - 10 cells, n PhobosCADN = 8 - 9 cells, n Gt ACR1CA = 6 cells). Kruskal- Wallis test with Dunn’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001.
A1, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/Adeno-Associated+Virus+2+%2F+AAV2+(VP1)+Mouse+Monoclonal+Antibody/pm36996872-802-34-35
Average 91 stars, based on 1 article reviews
a1 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

91
OriGene anti aav vp1 vp2
(A) Left: Engineering strategy yielding Aion and <t>Phobos</t> CADN , two new blue-shifted, step-function ACRs with temporally extended conducting states. Mutation of the D156 residue to either C or N (yielding Aion and Phobos CADN , respectively) greatly slows down the closing kinetics of the ACRs compared to its parental construct <t>Phobos</t> <t>CA</t> . The generated variants are highlighted by a black frame. Right: Schematic of Aion indicating point mutations (triangles) at the relative position within the respective transmembrane helix. (B) Representative photocurrent traces of the slow-cycling ACRs Phobos CA , Aion, Phobos CADN , and Gt ACR1 CA activated by a short 20 ms light pulse at indicated wavelengths and irradiance of 3.35 mW/mm 2 (460nm) and 3.14 mW/mm 2 (505 nm). (C) Left: quantification of peak photocurrent ( I p ) and photocurrent 30 s post illumination ( I 30s ) for each ACR. Right: photocurrent ratio at 30 s compared to the peak. (D) Normalized photocurrent after light shutoff. (E) Closing time constants (τ off ) for each ACR. For (C) and (E), black lines correspond to mean values ± SEM, and circles are single measurement data points (n PhobosCA = 5 -6 cells, nAion = 5 - 10 cells, n PhobosCADN = 8 - 9 cells, n Gt ACR1CA = 6 cells). Kruskal- Wallis test with Dunn’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001.
Anti Aav Vp1 Vp2, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/Adeno-Associated+Virus+2+%2F+AAV2+(VP1+%2F+VP2)+Mouse+Monoclonal+Antibody/pm36996872-803-31-35
Average 91 stars, based on 1 article reviews
anti aav vp1 vp2 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

90
OriGene bm5012su
(A) Left: Engineering strategy yielding Aion and <t>Phobos</t> CADN , two new blue-shifted, step-function ACRs with temporally extended conducting states. Mutation of the D156 residue to either C or N (yielding Aion and Phobos CADN , respectively) greatly slows down the closing kinetics of the ACRs compared to its parental construct <t>Phobos</t> <t>CA</t> . The generated variants are highlighted by a black frame. Right: Schematic of Aion indicating point mutations (triangles) at the relative position within the respective transmembrane helix. (B) Representative photocurrent traces of the slow-cycling ACRs Phobos CA , Aion, Phobos CADN , and Gt ACR1 CA activated by a short 20 ms light pulse at indicated wavelengths and irradiance of 3.35 mW/mm 2 (460nm) and 3.14 mW/mm 2 (505 nm). (C) Left: quantification of peak photocurrent ( I p ) and photocurrent 30 s post illumination ( I 30s ) for each ACR. Right: photocurrent ratio at 30 s compared to the peak. (D) Normalized photocurrent after light shutoff. (E) Closing time constants (τ off ) for each ACR. For (C) and (E), black lines correspond to mean values ± SEM, and circles are single measurement data points (n PhobosCA = 5 -6 cells, nAion = 5 - 10 cells, n PhobosCADN = 8 - 9 cells, n Gt ACR1CA = 6 cells). Kruskal- Wallis test with Dunn’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001.
Bm5012su, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/Adeno-Associated+Virus+2+%2F+AAV2+(Replicase+Rep+78%2C+68%2C+52%2C+40)+Mouse+Monoclonal+Antibody/pmc04135950-94-93-89
Average 90 stars, based on 1 article reviews
bm5012su - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

86
Pfizer Inc pennsylvania vector core aav2
(A) Left: Engineering strategy yielding Aion and <t>Phobos</t> CADN , two new blue-shifted, step-function ACRs with temporally extended conducting states. Mutation of the D156 residue to either C or N (yielding Aion and Phobos CADN , respectively) greatly slows down the closing kinetics of the ACRs compared to its parental construct <t>Phobos</t> <t>CA</t> . The generated variants are highlighted by a black frame. Right: Schematic of Aion indicating point mutations (triangles) at the relative position within the respective transmembrane helix. (B) Representative photocurrent traces of the slow-cycling ACRs Phobos CA , Aion, Phobos CADN , and Gt ACR1 CA activated by a short 20 ms light pulse at indicated wavelengths and irradiance of 3.35 mW/mm 2 (460nm) and 3.14 mW/mm 2 (505 nm). (C) Left: quantification of peak photocurrent ( I p ) and photocurrent 30 s post illumination ( I 30s ) for each ACR. Right: photocurrent ratio at 30 s compared to the peak. (D) Normalized photocurrent after light shutoff. (E) Closing time constants (τ off ) for each ACR. For (C) and (E), black lines correspond to mean values ± SEM, and circles are single measurement data points (n PhobosCA = 5 -6 cells, nAion = 5 - 10 cells, n PhobosCADN = 8 - 9 cells, n Gt ACR1CA = 6 cells). Kruskal- Wallis test with Dunn’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001.
Pennsylvania Vector Core Aav2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2/8+aav2+core+gfp+pennsylvania+tbg+vector/pm28467931-450-82-99
Average 86 stars, based on 1 article reviews
pennsylvania vector core aav2 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).

Journal: ACS Synthetic Biology

Article Title: Enhanced Epigenetic Modulation via mRNA-Encapsulated Lipid Nanoparticles Enables Targeted Anti-inflammatory Control

doi: 10.1021/acssynbio.5c00188

Figure Lengend Snippet: Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).

Article Snippet: Following validation, these constructs served as templates for AAV2-Cas9 and AAV2-mCherry viral production by PackGene Biotech, LLC.

Techniques: Control, Quantitative RT-PCR, Expressing, Immunohistochemical staining, Staining, Negative Control, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

(A) Left: Engineering strategy yielding Aion and Phobos CADN , two new blue-shifted, step-function ACRs with temporally extended conducting states. Mutation of the D156 residue to either C or N (yielding Aion and Phobos CADN , respectively) greatly slows down the closing kinetics of the ACRs compared to its parental construct Phobos CA . The generated variants are highlighted by a black frame. Right: Schematic of Aion indicating point mutations (triangles) at the relative position within the respective transmembrane helix. (B) Representative photocurrent traces of the slow-cycling ACRs Phobos CA , Aion, Phobos CADN , and Gt ACR1 CA activated by a short 20 ms light pulse at indicated wavelengths and irradiance of 3.35 mW/mm 2 (460nm) and 3.14 mW/mm 2 (505 nm). (C) Left: quantification of peak photocurrent ( I p ) and photocurrent 30 s post illumination ( I 30s ) for each ACR. Right: photocurrent ratio at 30 s compared to the peak. (D) Normalized photocurrent after light shutoff. (E) Closing time constants (τ off ) for each ACR. For (C) and (E), black lines correspond to mean values ± SEM, and circles are single measurement data points (n PhobosCA = 5 -6 cells, nAion = 5 - 10 cells, n PhobosCADN = 8 - 9 cells, n Gt ACR1CA = 6 cells). Kruskal- Wallis test with Dunn’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001.

Journal: bioRxiv

Article Title: Temporally extended and reversible neuronal silencing with Aion

doi: 10.1101/2022.02.25.481932

Figure Lengend Snippet: (A) Left: Engineering strategy yielding Aion and Phobos CADN , two new blue-shifted, step-function ACRs with temporally extended conducting states. Mutation of the D156 residue to either C or N (yielding Aion and Phobos CADN , respectively) greatly slows down the closing kinetics of the ACRs compared to its parental construct Phobos CA . The generated variants are highlighted by a black frame. Right: Schematic of Aion indicating point mutations (triangles) at the relative position within the respective transmembrane helix. (B) Representative photocurrent traces of the slow-cycling ACRs Phobos CA , Aion, Phobos CADN , and Gt ACR1 CA activated by a short 20 ms light pulse at indicated wavelengths and irradiance of 3.35 mW/mm 2 (460nm) and 3.14 mW/mm 2 (505 nm). (C) Left: quantification of peak photocurrent ( I p ) and photocurrent 30 s post illumination ( I 30s ) for each ACR. Right: photocurrent ratio at 30 s compared to the peak. (D) Normalized photocurrent after light shutoff. (E) Closing time constants (τ off ) for each ACR. For (C) and (E), black lines correspond to mean values ± SEM, and circles are single measurement data points (n PhobosCA = 5 -6 cells, nAion = 5 - 10 cells, n PhobosCADN = 8 - 9 cells, n Gt ACR1CA = 6 cells). Kruskal- Wallis test with Dunn’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: Phobos CA mutants (D156C/Aion, D156N, D156S, D156H) were generated by site-directed mutagenesis of our previously reported plasmid Phobos CA -citrine ( ) (Addgene #98218).

Techniques: Mutagenesis, Residue, Construct, Generated

Maximum-intensity projection images of two-photon stacks showing expression of Phobos CA -D156C ( A ), Phobos CA -D156N ( B ), Phobos CA -D156S ( C ), and Phobos CA -D156H ( D ) in CA1 pyramidal neurons after single-cell electroporation in organotypic hippocampal slice cultures. Fluorescence intensity is shown as inverted gray values. Opsin-citrine fluorescence (top row) was mainly localized at the plasma membrane in Phobos CA -D156C (A) and Phobos CA -D156N (B) expressing cells. However, Phobos CA -D156S (C) and Phobos CA -D156H (D) expressing neurons showed poor trafficking and strong protein accumulation in the soma. mCerulean was co-electroporated together with all opsin variants and served as a morphology marker (bottom row).

Journal: bioRxiv

Article Title: Temporally extended and reversible neuronal silencing with Aion

doi: 10.1101/2022.02.25.481932

Figure Lengend Snippet: Maximum-intensity projection images of two-photon stacks showing expression of Phobos CA -D156C ( A ), Phobos CA -D156N ( B ), Phobos CA -D156S ( C ), and Phobos CA -D156H ( D ) in CA1 pyramidal neurons after single-cell electroporation in organotypic hippocampal slice cultures. Fluorescence intensity is shown as inverted gray values. Opsin-citrine fluorescence (top row) was mainly localized at the plasma membrane in Phobos CA -D156C (A) and Phobos CA -D156N (B) expressing cells. However, Phobos CA -D156S (C) and Phobos CA -D156H (D) expressing neurons showed poor trafficking and strong protein accumulation in the soma. mCerulean was co-electroporated together with all opsin variants and served as a morphology marker (bottom row).

Article Snippet: Phobos CA mutants (D156C/Aion, D156N, D156S, D156H) were generated by site-directed mutagenesis of our previously reported plasmid Phobos CA -citrine ( ) (Addgene #98218).

Techniques: Expressing, Electroporation, Fluorescence, Clinical Proteomics, Membrane, Marker

( A ) Representative current traces of kinetically modified Phobos CA variants and Gt ACR1 CA . ACR variants were illuminated with 500 ms (row 1-4) or 20 ms (last row) actinic light at indicated wavelengths, while termination of photocurrents was accelerated with orange or red light for 10 s as indicated. ( B ) and ( C ) temporally expanded photocurrent traces as shown in (A) showing different modes of inactivation (B) and accelerated closing kinetics of Phobos CA variants (C). ( D ) Quantification of the residual photocurrent after orange or red-light application. While Gt ACR1 CA showed a 30 % photocurrent reduction when red light was applied 2 s post initial activation, application after 30 s caused partial re-opening of the channel. Phobos CA variants could be fully closed by orange light. (E) Quantification of the accelerated channel closing of Phobos CA variants with orange light.

Journal: bioRxiv

Article Title: Temporally extended and reversible neuronal silencing with Aion

doi: 10.1101/2022.02.25.481932

Figure Lengend Snippet: ( A ) Representative current traces of kinetically modified Phobos CA variants and Gt ACR1 CA . ACR variants were illuminated with 500 ms (row 1-4) or 20 ms (last row) actinic light at indicated wavelengths, while termination of photocurrents was accelerated with orange or red light for 10 s as indicated. ( B ) and ( C ) temporally expanded photocurrent traces as shown in (A) showing different modes of inactivation (B) and accelerated closing kinetics of Phobos CA variants (C). ( D ) Quantification of the residual photocurrent after orange or red-light application. While Gt ACR1 CA showed a 30 % photocurrent reduction when red light was applied 2 s post initial activation, application after 30 s caused partial re-opening of the channel. Phobos CA variants could be fully closed by orange light. (E) Quantification of the accelerated channel closing of Phobos CA variants with orange light.

Article Snippet: Phobos CA mutants (D156C/Aion, D156N, D156S, D156H) were generated by site-directed mutagenesis of our previously reported plasmid Phobos CA -citrine ( ) (Addgene #98218).

Techniques: Modification, Activation Assay